SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Gufic Biosciences Ltd

BSE: 509079 NSE: GUFICBIO ISIN: INE742B01025
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Gufic Biosciences Ltd belong to?
Gufic Biosciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Gufic Biosciences Ltd a good quality company?
Gufic Biosciences Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Gufic Biosciences Ltd undervalued or overvalued?
Gufic Biosciences Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Gufic Biosciences Ltd a good buy now?
Gufic Biosciences Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Gufic Biosciences Ltd?
Gufic Biosciences Ltd revenue growth is 1.6% for FY-2025 , which is below its 5 year CAGR of 16.7% , indicating slower growth.
Q.2 Gross Profit margin of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.5% for FY-2025 , which is below its 5 year median of 14.3% , indicating decreasing margins.
Q.3 Operating Profit Margin of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 16.92% for FY-2025 , which is below its 5 year median of 18.55% indicating decreasing margins.
Q.4 Net Profit Margin of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Net Profit Margin is 8.53% for FY-2025 , is below with its 5 year median of 10.68%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 10.5 14.3
Operating Profit Margin 16.92 18.55
Net Profit Margin 8.53 10.68
Q.5 Return on Asset of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Return on Asset is 6.18%, which is below its 5 year historical median of 10.71%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Return on equity is 12.34% for FY-2025 , which is below its historical median of 25.84%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Return on capital employed is 13.51% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Cash conversion cycle is 83 days, above its historical median of 55 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.97 1.16
ROE 12.34 25.84
ROCE 13.51 23.23
Cash Conversion Cycle 83 days 55 days
Q.9 Debt to Equity ratio of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Debt-to-Equity ratio is 0.52 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Gufic Biosciences Ltd?
Gufic Biosciences Ltd Debt to cash flow from operations is 2.53 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Gufic Biosciences Ltd?
Promoters hold 72.50% of the Gufic Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Gufic Biosciences Ltd vs industry peers?
Gufic Biosciences Ltd revenue CAGR is 16.69% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 819.8 137.1
Gross Profit 86.1 15.1
Operating Profit 136 16
Net Profit 70 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.97 0.8
ROE 12.34 8.91
ROCE 13.51 11.59
Cash Conversion Cycle (days) 83.27 76

Valuation & price assessment

Q.1 Stock return of Gufic Biosciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21.5% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 21.5% 21.3% 13.3% -13.9%
Q.3 Valuation ratios of Gufic Biosciences Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 60.05 46.60 40.28
Price to Book 4.71 5.60 2.77
Price to Sales 3.4 2.09 2.65
EV to EBITDA 24.36 17.79 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×